Oxford Nanopore raises $41 million via private placement of ordinary shares

Oxford Nanopore Technologies Ltd., the UK-based developers of nanopore technology for the direct, electronic analysis of single molecules, today announced that it has raised £25 million ($41 million) in new funding via a private placement of ordinary shares in the Company.

The funds will support further development, external technology validation and production capabilities for the Company's proprietary technology for molecular analysis applications that include DNA sequencing and protein analysis. In addition to the development of techniques using biological nanopores, Oxford Nanopore has also strengthened existing projects and collaborations in the development of solid-state nanopores.

The round was funded by existing and new institutional and individual investors from the US and UK, including Lansdowne Partners, IP Group, Invesco Perpetual, Redmile Group, Illumina and other undisclosed investors. The Company has previously raised £49 million since its formation in 2005.

"We are delighted to welcome several exceptional new investors and thank our existing high-calibre shareholders for their ongoing support as we continue to develop the next generation of molecular analysis system," said Dr Gordon Sanghera, CEO of Oxford Nanopore.

"Our investors share our excitement about the Oxford Nanopore DNA sequencing system that is designed to meet the diverse needs of a range of scientific users. In addition, last year we noted that the development of our platform technology, GridIONTM, was advanced enough to merit the addition of a new project to develop techniques for electronic protein analysis. This programme has yielded substantial progress and we look forward to further progress for Oxford Nanopore in 2011."

The Oxford Nanopore platform technology, GridION, consists of a scalable modular instrument and self-contained consumable cartridge. GridION is adaptable for the analysis of different types of molecules including DNA and proteins by changing the types of nanopore included in the cartridge.

The Company's technology integrates techniques from disciplines that include nanopore science, electronics, high-speed data processing, fluidics and software development. Oxford Nanopore has built broad expertise and an intellectual property estate of more than 250 patents and patent applications in nanopore sensing technology, through a combination of in-house discoveries and a network of academic collaborations. New funds will also be used to support the Company's leadership position in current and future nanopore science. For example the Oxford Nanopore recently extended various academic partnerships, including an agreement with Harvard University that added graphene to an existing project in solid-state nanopore technology.

The placement of ordinary shares in the Company under this fundraising does not constitute an offer of the Company's shares to the public. No shares in the Company will be offered or sold to any person except in circumstances which have not resulted and will not result in an offer to the public.


Oxford Nanopore Technologies


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Nanopore Technologies. (2019, June 20). Oxford Nanopore raises $41 million via private placement of ordinary shares. News-Medical. Retrieved on September 23, 2021 from https://www.news-medical.net/news/20110426/Oxford-Nanopore-raises-2441-million-via-private-placement-of-ordinary-shares.aspx.

  • MLA

    Oxford Nanopore Technologies. "Oxford Nanopore raises $41 million via private placement of ordinary shares". News-Medical. 23 September 2021. <https://www.news-medical.net/news/20110426/Oxford-Nanopore-raises-2441-million-via-private-placement-of-ordinary-shares.aspx>.

  • Chicago

    Oxford Nanopore Technologies. "Oxford Nanopore raises $41 million via private placement of ordinary shares". News-Medical. https://www.news-medical.net/news/20110426/Oxford-Nanopore-raises-2441-million-via-private-placement-of-ordinary-shares.aspx. (accessed September 23, 2021).

  • Harvard

    Oxford Nanopore Technologies. 2019. Oxford Nanopore raises $41 million via private placement of ordinary shares. News-Medical, viewed 23 September 2021, https://www.news-medical.net/news/20110426/Oxford-Nanopore-raises-2441-million-via-private-placement-of-ordinary-shares.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Oxford Nanopore Technologies partners with UK Government to roll out LamPORE, a new generation of COVID-19 test